Fetroja
Payments companies reported to CMS as associated with Fetroja. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Fetroja, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Fetroja
These are the largest totals companies reported as associated with Fetroja. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Juan Diaz | Altamonte Springs, FL | Infectious Disease | $136,782.48 |
| Christian Sandrock | Sacramento, CA | Internal Medicine | $124,145.99 |
| Stephen Marcella | New Brunswick, NJ | Internal Medicine | $107,622.42 |
| Gary Noel | North Caldwell, NJ | Pediatric Infectious Diseases | $100,458.43 |
| Arthur Jeng | Sylmar, CA | Infectious Disease | $98,005.95 |
| Javeed Siddiqui | Roseville, CA | Infectious Disease | $94,453.35 |
| Bruce Friedman | Augusta, GA | Critical Care Medicine (Internal Medicine) | $92,324.90 |
| Joshua Rosenberg | Brooklyn, NY | Critical Care Medicine (Internal Medicine) | $81,282.82 |
| Fariborz Rezai | Livingston, NJ | Critical Care Medicine (Internal Medicine) | $80,991.71 |
| Ramzy Rimawi | Atlanta, GA | Critical Care Medicine (Internal Medicine) | $63,126.01 |
Prescribed Fetroja?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.